Registered Attendees

Registered Attendees

Print This Page

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Close Window
Keystone Resort Floorplan

Keystone Resort Floorplan

Print This Page



Close Window

This meeting took place in 2014



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Fibrosis: From Bench to Bedside (C4)


Organizer(s) Jeremy S. Duffield, Steven R. Ledbetter and John P. Iredale
March 23—28, 2014
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Nov 20, 2013
Abstract Deadline: Dec 18, 2013
Scholarship Deadline: Nov 20, 2013
Discounted Registration Deadline: Jan 21, 2014

Sponsored by Gilead Sciences, Inc., InterMune, Inc., MedImmune, Shire Human Genetic Therapies and Takeda Pharmaceutical Company Limited

Summary of Meeting:
Fibrosis of all the internal organs is increasingly recognized as a deleterious and ominous consequence of, normal aging, repetitive subclinical tissue injury or severe persistent tissue injury. Fibrosis is increasingly seen as the next broad-ranging target for therapeutics after Cancer, and there is now a rush to first-in-class therapeutics. The primary cell that lays down fibrotic tissue is the myofibroblast. Until very recently, the biology of myofibroblasts is relatively undeveloped due to a lack of definitive markers, and lack of clear ontogeny. This meeting: 1) Brings together biotech, pharma and academia in a seamless meeting. 2) Focuses on fibrosis as an abnormal wound healing or tissue repair response identifying aberrant developmental pathways, and progenitor cell responses. c) Has a broad focus on basic biology of myofibroblasts, their progenitors, progenitor ontogeny, and their interaction with the immune system in disease. d) Focuses on fibrosis as a normal part of aging and the epigenetics involved in maintaining myofibroblasts in an activated state. e) Includes a full session on biomarkers; among the major blocks to progress is the lack of biomarkers. f) Feature formal presentations from biotech/pharma on the most promising new therapeutics in development or clinical trial. All of these highlighted areas are underdeveloped and are rapidly changing. The Keystone Symposia Fibrosis meeting is intended to be the premier international meeting for anyone with an interest in this disease process. The meeting brings together academics from a broad range of interest areas, including cancer, vascular biology, stem cell biology and tissue regeneration, as well as those with organ specific-interests.

View Scholarships/Awards

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 23

16:00—20:00
Arrival and Registration

18:00—20:00
Mixer


MONDAY, MARCH 24

07:00—08:00
Breakfast

08:00—08:15
Introduction
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Jeremy S. Duffield, Biogen Idec, USA

08:15—09:15
Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Steven R. Ledbetter, Genzyme Corporation, USA

* Jeremy S. Duffield, Biogen Idec, USA

Harry (Hal) C. Dietz, Johns Hopkins University School of Medicine, USA
Insights Regarding the Pathogenesis and Treatment of Scleroderma

09:15—12:00
Senescence, Cell Stress and the Fibrogenic Response
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Steven R. Ledbetter, Genzyme Corporation, USA

* Erwin P. Böttinger, Mount Sinai School of Medicine, USA

Judith Campisi, Buck Institute for Research on Aging, USA
The Role of Cellular Senescence in Inflammation and Fibrosis

Dean Sheppard, University of California, San Francisco, USA
Fibroblast alphav Integrins as Therapeutic Targets in Tissue Fibrosis

John P. Iredale, University of Edinburgh, UK
Macrophages and Resolution of Liver Fibrosis

David Lagares, Massachusetts General Hospital, USA
Short Talk: “Fibronucleation” and Stiffness Gradients Drive Tissue Fibrosis by Promoting Fibroblast Recruitment and Activation through Cell “Durotaxis”

Massimiliano Mellone, University of Southampton, UK
Short Talk: Fibroblast to Myofibroblast Differentiation in Fibrosis and Tumor Microenvironment: Role of DNA Damage Response (DDR) Pathway

Neetu Razdan, Rutgers University, USA
Short Talk: Telomere Dysfunction Is a Mediator of Myofibroblast Transdifferentiation

09:55—10:15
Coffee Break

12:00—13:00
Poster Setup

13:00—22:00
Poster Viewing

12:00—17:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

17:00—19:15
Metabolic Pathways in Fibrogenesis
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Thomas A. Wynn, NIAID, National Institutes of Health, USA

* John Varga, Northwestern University, Feinberg School of Medicine, USA

Rik Derynck, University of California, San Francisco, USA
Control of Epithelial-Mesenchymal Transition by TGF-beta Receptor Presentation

Erwin P. Böttinger, Mount Sinai School of Medicine, USA
Mitochondrial Dysfunction and Renal Fibrogenesis

Nelson Chau, RaNA Therapeutics, USA
Oligonucleotide-Mediated Antagonism of Dysregulated MicroRNAs Represents a Novel Therapeutic Strategy for Treatment of Fibrosis

Benjamin Korman, Northwestern University, USA
Short Talk: Adipocyte-Specific Ablation of PPAR-gamma Co-Repressor NCoR Modulates Metabolism and Attenuates Experimental Skin Fibrosis

Monique Bernard, University of Montreal Hospital Centre - Research Centre, CRCHUM, Canada
Short Talk: mTORC2 Links Autophagy and Myofibroblast Differentiation

19:15—20:15
Social Hour with Lite Bites

19:30—22:00
Poster Session 1:
1A Fate Mapping Studies
1B Metabolic/Stress/Senescence Pathways
1C Scleroderma/Systemic Sclerosis
1D New Insights from Screens
1E Reprogramming/Epigenetics
1F MicroRNA
1G Perivasculature


* David A. Brenner, University of California, San Diego Health Sciences, USA

* Jelena Mann, Newcastle University, UK

* Boris Hinz, University of Toronto, Canada


TUESDAY, MARCH 25

07:00—08:00
Breakfast

08:00—11:45
Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Andrew M. Tager, Massachusetts General Hospital, USA

Jeremy S. Duffield, Biogen Idec, USA
Mechanisms of Perivascular Cell Activation in Disease

Lucie Peduto, Institut Pasteur, France
The Fate and Function of ADAM12(+) Perivascular Cells in Injury and Fibrosis

Christian Göritz, Karolinska Institutet, Sweden
The Role of Pericytes in Central Nervous System Scarring and Fibrosis

Jonathan M. Graff, University of Texas Southwestern Medical Center, USA
Adipose Stem Cells: Give me a Pill and not a Treadmill

Ingmar Mederacke, Columbia University, USA
Short Talk: Fate Tracing Reveals Hepatic Stellate Cells as Main Contributors to the Myofibroblast Pool in Toxic, Biliary and Fatty Liver Disease

Tien Peng, University of Pennsylvania, USA
Short Talk: Hedgehog Regulates Fibroblast Proliferation during Normal Tissue Homeostasis and Fibrotic Repair

* Andrew Leask, University of Western Ontario, Canada
Short Talk: Skin Progenitor Cells Contribute to Bleomycin-Induced Skin Fibrosis

09:20—09:40
Coffee Break

11:45—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:45—14:30
On Own for Lunch and Recreation

14:30—16:30
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea?

* Heather A. Arnett, Amgen Inc., USA

* Kamran Atabai, University of California, San Francisco, USA

Martin L. Decaris, KineMed Inc., USA
Proteomic Quantitation of Altered Extracellular Matrix Protein Turnover in Animal Models of Pulmonary Fibrosis

Terrie-Anne Cock, Pharmaxis, Australia
Inhibition of TGF-beta Signaling and LOXL2: Pharmaxis’ Dual Small Molecule Approach to Treat Fibrosis

Ming-Hui Fan, University of Pittsburgh, USA
Fibroblast Activation Protein (FAP), An Endogenous Regulator of Fibrosis, Participates in Collagen Catabolism

Thomas H. Barker, Georgia Institute of Technology, USA
A CD90/Fyn/alphavbeta3 Integrin Mechanosignaling Axis Modulates ECM Rigidity Sensing in Lung Fibrosis

Franco Klingberg, University of Toronto, Canada
Organized Is More Efficient: Pre-Stress in the ECM Enhances Activation of Latent TGF-beta1 by Myofibroblast Contraction

Peter D. Mariner, University of Colorado, USA
Dynamic Hydrogel Platform for Studying the Effects of Environmental Stiffness on Myofibroblast Activation

Nathan Sandbo, University of Wisconsin, USA
Myofibroblasts Exhibit Elevated Fibronectin Assembly that Is Intrinsic to its Contractile Phenotype

14:30—16:30
Workshop 1B: How Best to Regulate Myofibroblast Activation

* Harry (Hal) C. Dietz, Johns Hopkins University School of Medicine, USA

* Tatiana Kisseleva, University of California, San Diego, USA

Sergei P. Atamas, University of Maryland School of Medicine, USA
Deciphering Mechanisms of IL-33-Driven Fibrosis

Christian Beyer, University of Erlangen-Nuremberg, Germany
The Soluble Guanylate Cyclase (sGC) Inhibits Fibrosis by Interfering with Non-Canonical TGFbeta-Signaling

Michael P. Czubryt, University of Manitoba, Canada
Regulation of Myocardial Fibrogenesis and Fibroblast Phenotype by Scleraxis

Emily Hamburg, Case Western Reserve University, USA
Cell Autonomous Mechanisms of Fibrosis Due to Elevated beta-Catenin Activity in Dermal Fibroblasts

Alison E. John, University of Nottingham, UK
Alveolar TGF-beta Activation and Lung Homeostasis Is Regulated by Epithelial Gq/G11 Signaling

Katherine M. Martin, University of Manchester, UK
Integrin Beta1 Regulates Hepatic Stellate Cell Activation

Saimir Luli, Newcastle University, UK
A Novel Liposomal Technology to Selectively Target Hepatic Myofibroblasts

16:30—17:00
Coffee Available

17:00—19:15
Innate and Adaptive Pathways in Fibrogenesis
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* John P. Iredale, University of Edinburgh, UK

* Timothy Radstake, University Medical Center Utrecht, Netherlands

Paul Kubes, University of Calgary, Faculty of Medicine, Canada
Intravascular Immunity in the Development and Resolution of Sterile Injury

Thomas A. Wynn, NIAID, National Institutes of Health, USA
Macrophage Subsets in Type-2-Dependent Fibrosis

Scott L. Friedman, Mount Sinai School of Medicine, USA
Autophagy Fuels Mesenchymal Cell Fibrogenesis in Liver and Other Tissues

Brigid M. O'Flaherty, Emory University, USA
Short Talk: Evaluating the Role of MHV68 M1 Induced Vbeta4+CD8+ T Cell Expansion in Development of Pulmonary Fibrosis

Christian Stockmann, PARCC - Paris Cardiovascular Research Center, France
Short Talk: Sinusoidal Remodeling by Myeloid Cell-Derived VEGF Is Required for the Resolution of Liver Fibrosis

19:15—20:15
Social Hour with Lite Bites

19:30—22:00
Poster Session 2:
2A Infectious Mechanisms
2B New Targets
2C Innate/Adaptive Immunity
2D Underrepresented Organs/Diseases
2E Repair/Regeneration

* Lynn M. Schnapp, Medical University of South Carolina, USA

* Paul Kubes, University of Calgary, Faculty of Medicine, Canada

* Paul W. Noble, Cedars-Sinai Medical Center, USA


WEDNESDAY, MARCH 26

07:00—08:00
Breakfast

08:00—11:45
Established and Promising Therapies Entering Clinical Development
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Dean Sheppard, University of California, San Francisco, USA

* Mark L. Lupher, Jr., Muregen, LLC, USA

Paul W. Noble, Cedars-Sinai Medical Center, USA
Update on Clinical Trials in Idiopathic Pulmonary Fibrosis

Naftali Kaminski, Yale University School of Medicine, USA
MicroRNAs in Lung Fibrosis

Elizabeth G. Trehu, Promedior, Inc., USA
and

Bernt van den Blink, Erasmus MC, Netherlands
PRM-151 in Idiopathic Pulmonary Fibrosis and Myelofibrosis

Andrew M. Tager, Massachusetts General Hospital, USA
Lysophosphatidic Acid (LPA)-LPA1 Signaling in Fibrogenesis

Jeffrey R. Crosby, ISIS Pharmaceuticals, USA
Short Talk: Inhaled Antisense Oligonucleotides for the Treatment of Pulmonary Fibrosis: The Role of Osteopontin in Mouse Models of Disease

Cédric Szyndralewiez, Genkyotex, Switzerland
Short Talk: The NADPH Oxidase (NOX) Inhibitor GKT137831 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)

Timothy Radstake, University Medical Center Utrecht, Netherlands
Short Talk: The Chemokine CXCL4 Is a Novel biomarker in Systemic Sclerosis Linking Inflammation, Endothelial Dysfunction and Fibrosis

Mushriq Al-Jazrawe, University of Toronto, Canada
Short Talk: Preventing Fibrosis by Targeting beta-Catenin: A Preclinical Study of Topical Nefopam

09:20—09:40
Coffee Break

11:45—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:45—17:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

17:00—19:15
Promising New Pathways in Fibrogenesis
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Paul W. Noble, Cedars-Sinai Medical Center, USA

* Victoria Smith, Gilead Sciences, USA

Heather A. Arnett, Amgen Inc., USA
Identifying Novel Myofibroblast Pathways in IPF Lungs

Robert Lafyatis, Boston University School of Medicine, USA
Anti-TGF-beta/Fresolimumab Inhibition of Skin Fibrosis and TGF-beta-Regulated Biomarker Gene Expression in Patients with Systemic Sclerosis

Greg R. Dressler, University of Michigan, USA
Novel TGF-beta Superfamily Regulators in Renal Fibrosis

James P. Pritchett, University of Manchester, UK
Short Talk: A Role for Mechano-Transduction via Yap/Taz in Hepatic Stellate Cell Activation

Cristi L. Galindo, Vanderbilt University, USA
Short Talk: Neuregulin Inhibits Cardiac Fibrosis and Mediates Anti-Fibrotic Signaling in Cardiac Fibroblasts

19:15—20:15
Social Hour with Lite Bites

19:30—22:00
Poster Session 3:
3A Clinical Trials
3B Biomarkers/Monitoring/Devices
3C New Models
3D Signaling
3E Matrix Signaling to Cells

* Bruno Péault, University of California, Los Angeles, USA

* Stuart Forbes, University of Edinburgh, UK

* Andrew M. Tager, Massachusetts General Hospital, USA


THURSDAY, MARCH 27

07:00—08:00
Breakfast

08:00—11:45
Resolution of Fibrosis and Pathways of Repair and Regeneration
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Jeremy S. Duffield, Biogen Idec, USA

* Tien Peng, University of Pennsylvania, USA

Bruno Péault, University of California, Los Angeles, USA
Role of Vascular Pericytes in Normal and Pathologic Tissue Regeneration

Gabrielle Kardon, University of Utah, USA
Interactions between Muscle Stem Cells, Fibroblasts and Macrophages Are Critical for Muscle Regeneration

Stuart Forbes, University of Edinburgh, UK
Liver Regeneration

Michelle D. Tallquist, University of Hawaii, USA
Cardiac Resident Mesenchymal Cells in Organogensis and Fibrosis

Dario R. Lemos, University of British Columbia, Canada
Short Talk: The Innate Immune Response Modulates Fibrosis during Skeletal Muscle Regeneration via TNF-alpha/TGF-beta Signaling on Mesenchymal Multipotent Cells

Laura Johnson, University of Michigan, USA
Short Talk: Intestinal Organoids: A Model of Intestinal Fibrosis

Wilder Scott, University of British Columbia, Canada
Short Talk: Analysis of Mesenchymal Stromal Cell Fate in Tissue Regeneration

Norihiko Takeda, University of Tokyo, Japan
Short Talk: Roles of Macrophages Hypoxia Signaling in Cardiac Fibrosis

09:20—09:40
Coffee Break

11:45—14:30
On Own for Lunch and Recreation

14:30—16:30
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices

* Scott L. Friedman, Mount Sinai School of Medicine, USA

Edford Sinkala, University Teaching Hospital, Zambia
High Concentration of Fibrotic and Inflammatory Markers among Patients with Schistosomal Liver Diseases

Scott M. Turner, Kinemed Inc., USA
Identification of a Putative Serum Protein Biomarker for Noninvasive Measurement of Fibrogenesis: Correlation with Hepatic Collagen Synthesis and Histological Score in Humans

John A. Baugh, Conway Institute, Ireland
Serum Amyloid P-Component: A Novel Biomarker and Potential Treatment for Left Ventricular Remodelling and Heart Failure

Thomas H. Barker, Georgia Institute of Technology, USA
A New Modality for Imaging Fibrosis - Detection of an Extracellular Integrin “Switch” A Conformation Specific Antibody against Fibronectin for Imaging of Fibrosis

Florin L. Craciun, Brigham & Women's Hospital/ Harvard Medical School, USA
Discovery of 12 New Candidate Biomarkers for Chronic Kidney Disease: From Mouse Models to Human Patients

Claire Emson, Kinemed, Inc, USA
Collagen Synthesis Rate Distinguishes between Early and Late Diffuse Scleroderma Subjects

Jose D. Herazo-Maya, Yale University, USA
A 52 Peripheral Blood Gene Signature Predicts Poor Outcome and Disease Progression in Idiopathic Pulmonary Fibrosis

Mette Juul Nielsen, Nordic Bioscience, Denmark
Serological Markers of Extracellular Matrix Remodeling Enables Early Diagnosis and Predicts Fibrosis Progression of Chronic Hepatitis C

Karl Kossen, Intermune, Inc., USA
Plasma MMP-7 Predicts Mortality in Idiopathic Pulmonary Fibrosis

14:30—16:30
Workshop 2B: New Pathways/Drugs from SCREENS

* Linda C. Burkly, Biogen Idec, Inc., USA

* Stuart Forbes, University of Edinburgh, UK

David Zhang, Mount Sinai School of Medicine, USA
A Genomics Strategy Highlights Hand2 Regulation in Hepatic Stellate Cell Activation

Kamran Atabai, University of California, San Francisco, USA
Functional Genomic Screen Identifies Novel Mediators of Collagen Uptake and Turnover

Xavier Espanel, Inventiva, France
Development and Automation of a Fibrotic Phenotypic Screening Using a High Content Screening Approach

David W. Griggs, St. Louis University, USA
Preclinical Development of Multi-Functional Integrin Antagonists for Treatment of Organ Fibrosis

John B. Nicholas, InterMune, Inc., USA
Phenotypic Screening for Inhibitors of Fibroblast to Myofibroblast Transition (FMT)

Kevin K. Kim, University of Michigan, USA
Overexpression of Id2 Transcription Factor Promotes Alveolar Epithelial Cell Proliferation and Attenuates Belomycin-Induced Pulmonary Fibrosis

Branko Stefanovic, Florida State University, USA
Discovery and Validation of a Potent Antifibrotic Drug with Unique Mechanism of Action

16:30—17:00
Coffee Available

17:00—19:00
Myofibroblast Reprogramming
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Naftali Kaminski, Yale University School of Medicine, USA

* Michelle D. Tallquist, University of Hawaii, USA

David A. Brenner, University of California, San Diego Health Sciences, USA
Myofibroblast Inactivation in the Resolution of Fibrosis

Jelena Mann, Newcastle University, UK
Epigenetics in Myofibroblast Reprogramming

Boris Hinz, University of Toronto, Canada
The Effect of the Mechanical Environment on Myofibroblast Development and Persistence

Eleni Stylianou, Lerner Research Institute, Cleveland Clinic, USA
Short Talk: Defining the Fibrotic DNA Methylome in Crohn’s Disease

19:00—19:10
Concluding Remarks
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Jeremy S. Duffield, Biogen Idec, USA

19:10—20:10
Social Hour with Lite Bites

20:00—23:00
Entertainment


FRIDAY, MARCH 28

 
Departure


*Session Chair †Speaker invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Gilead Sciences, Inc. InterMune, Inc.
MedImmune Shire Human Genetic Therapies
Takeda Pharmaceutical Company Limited
 

We gratefully acknowledge additional support for this conference from:

Genkyotex SA Myriad-RBM
Promedior, Inc.
 

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Promedior, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Amanda Deem, Assistant Director of Development, Email: AmandaD@keystonesymposia.org,
Phone:+1 970-262-2668

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676